Search clinical trials for: cabazitaxel XRP6258

Total 125 results

Sanofi

Completed

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

Malignant Solid Tumor - Malignant Nervous System Neoplasm

United States, Canada
AIO-Studien-gGmbH
Sanofi; ClinAssess GmbH

Terminated

A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) (CaBaMet)

Breast Cancer | Lung Cancer | Recurrent Brain Metastases | Progressive Brain Metastases

Germany
University of Alabama at Birmingham
Sanofi

Completed

Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC) | Metastatic NSCLC | Stage IV NSCLC

United States
Dr Anjali Zarkar
Sanofi

Completed

Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel (CabB1)

Transitional Cell Carcinoma

United Kingdom
Sanofi

Completed

A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

Solid Cancer

United States
Sanofi

Completed

Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy (GASTANA)

Gastric Cancer

Korea, Republic of
Sanofi

Completed

Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment

Neoplasm Malignant

Netherlands, Belgium, Spain, Italy, United Kingdom
Hellenic Cooperative Oncology Group
Sanofi

Completed

Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes

Breast Cancer

Greece
Sanofi

Completed

A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

France, Spain
Sanofi

Completed

Effect of Cabazitaxel on the QTc Interval in Cancer Patients (QT-Cab)

Neoplasms, Malignant

United States, Belgium, Denmark, Netherlands, Sweden
Sanofi

Completed

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

Neoplasm Malignant

United States
Sanofi

Completed

Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer

Canada, Norway, Spain, United States, Brazil, Chile, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Poland, Romania, Russian Federation, Ukraine
Case Comprehensive Cancer Center

Withdrawn

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

Castrate-resistant Metastatic Prostate Cancer
Sanofi

Completed

Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer (SWITCH)

Prostatic Neoplasms

Brazil
SCRI Development Innovations, LLC
Sanofi; GlaxoSmithKline; Novartis

Terminated

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

Metastatic Breast Cancer With Intracranial Metastases

United States
The Clatterbridge Cancer Centre NHS Foundation...
University of Liverpool

Not yet recruiting

Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome (CHROME)

Prostate Cancer
Jeffrey Yachnin M.D., PhD.
Sanofi

Completed

A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer (ConCab)

Metastatic Castration Resistant Prostate Cancer

Sweden
Krzysztof Misiukiewicz
Sanofi; Icahn School of Medicine at Mount Sinai

Completed

Cabazitaxel - PF Induction Chemotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
Vejle Hospital
Sanofi

Terminated

Cabazitaxel in Platinum Refractory Ovarian Cancer

Ovarian Cancer

Denmark
Azienda Socio Sanitaria Territoriale degli Spedali...
San Luigi Gonzaga Hospital

Unknown

Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines (CabACC)

Adrenocortical Carcinoma

Italy
Institut für Klinische Krebsforschung IKF GmbH...

Completed

Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer

Germany
Gustave Roussy, Cancer Campus, Grand Paris
Sanofi

Unknown

A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors (CABA-GCT)

Non-seminomatous Germ-cell Tumors

France
Rambam Health Care Campus

Completed

A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)

Urothelial Carcinoma

Israel
University Hospitals Bristol and Weston NHS Foundation...
Sanofi

Completed

A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis (JAVA-P)

Penile Neoplasm

United Kingdom
Brown University

Terminated

Cabazitaxel and Radiation For Patients With Prostate Cancer

Prostate Cancer

United States
European Organisation for Research and Treatment...
Sanofi

Completed

Ph II Cabazitaxel DD Liposarcoma

Dedifferentiated Liposarcoma

United Kingdom, Belgium, France, Italy
Vejle Hospital

Completed

Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy. (CaTo-ROC)

Ovarian Cancer

Denmark
Erasmus Medical Center
Sanofi

Withdrawn

Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs (CARVE)

Prostatic Neoplasms

Netherlands
Sanofi

Completed

Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer

Prostate Cancer Metastatic

India
Sanofi

Completed

Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

Prostate Cancer

Japan
Hellenic Cooperative Oncology Group
Sanofi

Completed

Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer (CABA-BONE)

Bone Metastatic Prostate Cancer

Greece
howard safran
The Miriam Hospital; Rhode Island Hospital; Roger Williams Medical Center

Terminated

Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen

Gastric Cancer | Gastrooesophageal Cancer | Esophageal

United States
M.D. Anderson Cancer Center
Sanofi

Withdrawn

Phase I/II Cabazitaxel for Recurrent Malignant Glioma

Brain Cancer
Sanofi

Terminated

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

Neoplasms, Malignant

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

Lymphadenopathy | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | Prostate Small Cell Carcinoma

United States
Associació per a la Recerca Oncologica, Spain

Unknown

Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)

Urothelium Transitional Cell Carcinoma

Spain, Netherlands
RWTH Aachen University

Terminated

Neoadjuvant Chemotherapy With Cabazitaxel (CLUBNET)

High-Risk Cancer

Germany
Sanofi

Completed

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer (PROSELICA)

Prostate Cancer

Korea, Republic of, Spain, United States, Argentina, Peru, Romania, Taiwan, United Kingdom, Belgium, Chile, Netherlands, Australia, Germany, Tunisia, Brazil, Canada, France, Hungary, Poland, Russian Federation, South Africa, Turkey
University of Southern California
National Cancer Institute (NCI); Sanofi

Terminated

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Diarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Hospital Clinico Universitario de Santiago
Fundación Ramón Domínguez

Terminated

Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment (COMETA)

Colorectal Cancer

Spain
Sanofi

Completed

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer (FIRSTANA)

Prostate Cancer

Australia, Portugal, Spain, Peru, Sweden, Romania, Russian Federation, Belarus, Israel, France, Italy, Denmark, Turkey, Germany, United States, Brazil, Canada, China, Czechia, Finland, Japan, Mexico, Poland, Taiwan, Ukraine
Medical University of South Carolina
Peregrine Pharmaceuticals

Terminated

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

Prostatic Neoplasms | Prostate Cancer

United States
Association Pour La Recherche des Thérapeutiques...

Completed

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel (CABASTY)

Prostate Cancer Metastatic

France, Germany
University of Alabama at Birmingham
Sanofi; Astellas Pharma Inc

Withdrawn

Phase I Trial of PACE for Metastatic Prostate Cancer

Metastatic Prostate Cancer

United States
UNICANCER

Completed

A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes (ORL03)

Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer

France
Jules Bordet Institute
Sanofi

Withdrawn

Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC (CRANIAL)

Breast Cancer | Non Small Cell Lung Cancer | Brain Metastasis

Belgium
Weill Medical College of Cornell University
Sanofi

Completed

Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Adenocarcinoma | Distal Esophageal Adenocarcinoma

United States
University of Ulm

Completed

Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme

Glioblastoma Multiforme (GBM) WHO Grade IV

Germany
Hellenic Oncology Research Group

Completed

Cabazitaxel in Relapsed and Metastatic NSCLC

NSCLC

Greece
University Hospital, Akershus
Sanofi

Terminated

Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

Testicular Cancer

Denmark, Norway, Italy, Sweden

Search clinical trials for: cabazitaxel XRP6258

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations